Navigation Links
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
Date:2/20/2008

to adjusted net income and earnings per share for the three and twelve months ended December 31, 2007 and 2006:

Table 4

Watson Pharmaceuticals, Inc.

Reconciliation Table

(Unaudited; in thousands except per share amounts)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

GAAP to adjusted net income

calculation

Reported GAAP net income (loss) $38,403 $(488,961) $141,030 $(445,005)

Adjusted for:

In-process research

and development - 497,800 - 497,800

Acquisition charges 1,494 12,288 12,782 12,477

(Gain) loss on sale of

assets - 149 (13,089) (3,546)

Non-cash impairment

charges 132 3,283 4,631 70,264

Early extinguishment

of debt 1,143 - 5,553 525

Legal settlements (800) 10,250 7,858 10,250

Income taxes (704) (7,512) (6,716) (31,781)

Adjusted net income 39,668 27,297 152,049 110,984

Add: Interest expense on

CODES, net of tax 1,873 1,876 7,779 7,361

Adjusted net income, adjusted

for interest on CODES $41,541 $29,173 $159,828 $118,345

Diluted earnings per share - GAAP

Diluted earnings (loss)

per share - GAAP $0.34 $(4.80) $1.27 $(4.37)

Basic weighted average common

shares outstanding
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Watson Receives FDA Approval for Generic Accuneb(R)
4. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
6. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
7. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... The new , Healthcare and Life ... today on PharmaBoardroom.com for free download , ... the Spanish economy in 2009, and the austerity measures that ... pragmatic in times of trouble. "Despite the crisis, ... European market, and the general conditions to invest are favorable ...
(Date:9/18/2014)... 18, 2014 A novel robotic system ... scanner is currently being tested as part of a ... in Boston with the aim of determining if the ... prostate cancer biopsies faster, more accurate, less costly, and ... has the potential to deliver prostate cancer therapies with ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Chinese Stem Cell Industry Report, 2014-2017" report to ... biological cells that can differentiate into specialized cells and ... Stem cell therapy can be applied to treatment of ... nervous system diseases, damage or lesion of liver, kidney ...
(Date:9/18/2014)... LOUIS , Sept. 18, 2014  U.S. biotech ... by signing an exclusive license for technology developed by ... control gene expression in plants, including for applications in ... The technology was developed under the ... officer at Kultevat and former president of the Danforth ...
Breaking Biology Technology:PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Kultevat obtains license of gene switch technology 2
... suffering from uterine fibroids, a debilitating condition that affects ... soon have reason for hope.  Halt Medical, a biomedical ... developing a minimally invasive procedure for treating the condition. ... Latin America at the NIH Global Fibroid Congress.   ...
... One of the requirements to keep trends in computer technology ... energy-efficient is faster writing and processing of data. In ... physicists at the Technische Universitaet Muenchen (TUM) and the Universitaet ... a solution. TUM physicists set a lattice of magnetic vortices ...
... 17, 2010 InterMune, Inc. (Nasdaq: ITMN ... to prepare for the commercialization of Esbriet™ (pirfenidone) in ... a positive CHMP opinion that is now awaiting ratification ... Chief Executive Officer and President of InterMune, said, "We ...
Cached Biology Technology:Halt Medical Presents Strong Results of International Fibroid Studies at National Institutes of Health Global Congress 2Electric current moves magnetic vortices 2InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 2InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 3InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 4InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 5InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 6
(Date:9/18/2014)... BUFFALO, N.Y. A sleep-promoting circuit located deep in ... deep sleep. Discovered by researchers at Harvard School of ... and Biomedical Sciences, this is only the second "sleep ... to be both necessary and sufficient to produce deep ... Neuroscience , the study demonstrates that fully half of ...
(Date:9/18/2014)... robotic system that can operate inside the bore of ... of a biomedical research partnership program at Brigham and ... if the robot, in conjunction with real-time MRI images, ... costly, and less discomforting for the patient. The novel ... therapies with greater precision. , Developed by a team ...
(Date:9/18/2014)... MADISON, Wis. No matter how many times ... as social, communicating creatures. , But by ... single-celled organisms radically alter their behavior to suit ... many of them are present, and act accordingly. ... the millions, it may change from innocuous to ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... that BioMed Central's Open Access journals are high quality ... Central have again received impact factors that compare well ... five titles in the top five of their specialty. ... they are respected by researchers, and are fast becoming ...
... Impressive impact factors prove that BioMed Central's Open Access ... Journals published by BioMed Central have again received impact ... was announced today, with five titles in the top ... these journals affirm that they are respected by researchers, ...
... in repairing lung damage, according to a team of scientists ... repair process in lung transplant patients. , Reporting in today's ... of The University of Texas Medical School at Houston, and ... that less than 1 percent of a certain type of ...
Cached Biology News:'Bionic' arm gives amputee sense of touch 2Open Access journals get impressive impact factors 2Circulating stem cells play small role in lung repair 2Circulating stem cells play small role in lung repair 3
MOUSE ANTI RAT RT1Ac Immunogen: PHA activated rat lymphocytes...
MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
Biology Products: